Clinical trials: Apoplexy; Stroke
Arterial Ischemic Stroke
A Proof of Concept Study to Evaluate the Safety of Afamelanotide in Patients With Acute Arterial Ischaemic Stroke (AIS)
The primary study objective is to assess the safety of afamelanotide while the secondary objective is to assess whether the therapy affects the size of the penumbra, by increasing blood flow, restoring oxygen supply to the brain…
- Trial name
- NCT04962503
- Testing
- Afamelanotide
- Where
- Australia
- Volunteers
- 6 people
- Sponsor
- Clinuvel Pharmaceuticals Limited
Chronic Stroke
Post-Stroke Walking Speed and Community Ambulation Conversion Study
The purpose of this randomized, controlled study is to collect performance data on the ability of an investigational device designed to digitally deliver Rhythmic Auditory Stimulation to improve walking speed in people who…
- Trial name
- NCT04121754
- Testing
- MR-001, Active Walking
- Where
- 8 sites in United States
- Volunteers
- 87 people
- Sponsor
- MedRhythms, Inc.
Stroke
Rehabilitation of the Stroke Hand at Home
The purpose of this research is to evaluate a therapy delivery system for stroke patients that provide accessible, affordable stroke care.
- Trial name
- HAAPI (NCT01144715)
- Testing
- Hand Mentor (TM) robotic stroke therapy device, Home Therapy Program
- Where
- 2 sites in United States
- Volunteers
- 99 people
- Sponsor
- Kinetic Muscles
Stroke
A Study of the Efficacy and Safety of Alteplase in Participants With Mild Stroke
PRISMS is a double-blind, multicenter, randomized, Phase IIIb study to evaluate the efficacy and safety of intravenous (IV) alteplase in participants with mild acute ischemic strokes that do not appear to be clearly disabling.
- Trial name
- PRISMS (NCT02072226)
- Testing
- Alteplase, Aspirin
- Where
- 88 sites in United States
- Volunteers
- 313 people
- Sponsor
- Genentech, Inc.
Post-Ischemic Stroke
A Study to Evaluate the Efficacy and Safety of Two Dose Strengths of Dalfampridine Extended Release Tablets.
The objective of this study is to determine the effect of two dose strengths of dalfampridine-Extended Release (ER) tablets, taken twice daily for 12 weeks, on stable walking deficits in subjects with post-ischemic stroke.
- Trial name
- MILESTONE℠ (NCT02271217)
- Testing
- dalfampridine-ER 7.5mg, dalfampridine-ER 10mg
- Where
- 74 sites in United States, Canada
- Volunteers
- 377 people
- Sponsor
- Acorda Therapeutics
Carotid Stenosis
Gadobutrol Enhanced MRA of the Supra-aortic Vessels
Subjects referred for a routine CTA (computed tomography angiography) or MRA (magnetic resonance angiography) will be invited to participate in the study and subjects will be involved in the study for between 2 and 12 days.
- Trial name
- GEMSAV (NCT01344447)
- Testing
- Gadobutrol (Gadovist, BAY86-4875)
- Where
- 56 sites in United States, Argentina and 12 more
- Volunteers
- 479 people
- Sponsor
- Bayer
Muscle Spasticity, Stroke
OnabotulinumtoxinA Treatment in Adult Patients With Upper Limb Spasticity
This is a safety and efficacy study of onabotulinumtoxinA in poststroke patients with upper limb spasticity.
- Trial name
- NCT02145676
- Testing
- onabotulinumtoxinA
- Where
- 2 sites in United States, Canada
- Volunteers
- 53 people
- Sponsor
- Allergan
Hemorrhagic Stroke, Intracerebral Hemorrhage (ICH)
Efficacy, Safety and Tolerability of BAF312 Compared to Placebo in Patients With Intracerebral Hemorrhage (ICH).
This is a randomized, placebo-controlled, subject and investigator-blinded study to evaluate efficacy, safety and tolerability of BAF312 in participants with intracerebral hemorrhage (ICH)
- Trial name
- NCT03338998
- Testing
- BAF312 solution, BAF312 tablet
- Where
- 11 sites in United States
- Volunteers
- 32 people
- Sponsor
- Novartis Pharmaceuticals
Nervous System Disorders
Dysport® Adult Upper Limb Spasticity
The purpose of this research study is to assess the efficacy of Dysport compared to placebo in improving muscle tone in hemiparetic subjects with upper limb spasticity due to stroke or traumatic brain injury.
- Trial name
- NCT01313299
- Testing
- Botulinum toxin type A
- Where
- 40 sites in United States, Belgium and 7 more
- Volunteers
- 243 people
- Sponsor
- Ipsen
Ischemic Stroke
Study to Test Sensitivity and Specificity of Passive Wave Pressure Device in Determining Ischemic Stroke
That the Jan Medical Nautilus NeuroWaveTM system provides significantly higher sensitivity to hyper acute ischemic stroke than does CT.
- Trial name
- NCT01643525
- Testing
- Nautilus NeuroWaveTM System
- Where
- 3 sites in United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Jan Medical, Inc.
Post-ischemic Stroke
Study to Evaluate the Long-Term Safety, Tolerability and Efficacy of Dalfampridine.
This is an extension study to evaluate the long-term safety, tolerability, and efficacy of two dose strengths of dalfampridine-ER.
- Trial name
- MILESTONE℠ (NCT02422940)
- Testing
- dalfampridine-ER 7.5 mg, dalfampridine-ER 10 mg
- Where
- 66 sites in United States, Canada
- Volunteers
- 294 people
- Sponsor
- Acorda Therapeutics
Stroke, Parkinson Disease
Videofluoroscopic Swallowing Study (VFSS)
The study procedure of simultaneous VFSS and DDS measurement will be completed in one day and the subject will be followed within 2 business days after the study procedure to monitor for adverse events.
- Conditions
- Stroke, Parkinson Disease, Multiple Sclerosis, Oropharyngeal Dysphagia
- Trial name
- PORSCHE (NCT03387267)
- Testing
- Dysphagia Detection System
- Where
- 13 sites in United States, Finland
- Volunteers
- 452 people
- Sponsor
- Société des Produits Nestlé (SPN)
Bleeding Disorder, Ischemic Stroke
XIENCE 28 USA Study
The XIENCE 28 USA Study is prospective, single arm, multi-center, open label, non-randomized trial to evaluate safety of 1-month (as short as 28 days) dual antiplatelet therapy (DAPT) in subjects at high risk of bleeding (HBR)…
- Conditions
- Bleeding Disorder, Ischemic Stroke, Hemorrhagic Stroke, Hematological Diseases
- Trial name
- NCT03815175
- Testing
- XIENCE, DAPT (aspirin and/or P2Y12 receptor inhibitor)
- Where
- 111 sites in United States, Austria and 13 more
- Volunteers
- 1,605 people
- Sponsor
- Abbott Medical Devices
Stroke
Portable EMG-triggered Hand Robot for Individuals After Stroke
This is an interventional pilot study investigating the feasibility of using the hand of hope (HOH) device for individuals with decreased hand function after stroke.
- Trial name
- NCT02364700
- Testing
- Hand of Hope (HOH)
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Rehab-Robotics Company Limited
Atrial Fibrillation (AF), Stroke
Safety and Tolerability of Abelacimab (MAA868) vs. Rivaroxaban in Patients With Atrial Fibrillation
The purpose of the ANT-006 study is to evaluate the bleeding profile of abelacimab relative to rivaroxaban in patients with atrial fibrillation (AF) at moderate-to-high risk of stroke.
- Trial name
- AZALEA-TIMI 71 (NCT04755283)
- Testing
- Abelacimab, Rivaroxaban
- Where
- 92 sites in United States, Canada and 5 more
- Volunteers
- 1,287 people
- Sponsor
- Anthos Therapeutics, Inc.
Stroke
1-year Clinical Outcomes in Recombinant Tissue Plasminogen Activator (Rt-PA) Treated Chinese Acute Ischaemic Stroke (AIS) Patients
The objective of the study is to find out the 1-year clinical outcomes among Acute Ischaemic Stroke (AIS) patients who were treated with intravenous (IV) Recombinant Tissue Plasminogen Activator (rt-PA) within 4.5 hours of…
- Trial name
- NCT05395338
- Testing
- rt-PA
- Where
- China
- Volunteers
- 12,551 people
- Sponsor
- Boehringer Ingelheim
Intracranial Atherosclerosis
Post Market Surveillance Study of the Wingspan Stent System
The primary objective of this study is to evaluate the rate of stroke and/or death in patients treated with the Wingspan Stent System, according to the Indications for Use, within 72 hours post procedure.
- Trial name
- WEAVE (NCT02034058)
- Testing
- Wingspan Stent System
- Where
- 26 sites in United States
- Volunteers
- 152 people
- Sponsor
- Stryker Neurovascular
Cerebrovascular Accident
A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GSK1358820 (Botulinum Toxin Type A) in Chinese Subjects With Post-stroke Upper Limb Spasticity
This trial is a multicenter, double-blind, randomized, placebo-controlled study to compare GSK1358820 (Botulinum Toxin Type A, also known as "OnabotulinumtoxinA" or "Botox") with placebo on the efficacy and safety of treatment in…
- Trial name
- NCT01153815
- Testing
- GSK1358820(Botulinum toxin type A)
- Where
- 13 sites in China
- Volunteers
- 170 people
- Sponsor
- GlaxoSmithKline
Stroke, Secondary Prevention
Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT ESUS)
This trial will enroll approximately 6,000 patients with recent embolic stroke of unknown source (ESUS). Patients will be randomized to dabigatran or acetylsalicyclic acid (ASA) (1:1 ratio) and have visits every three months.
- Trial name
- NCT02239120
- Testing
- optional ASA as comedication, ASA 100 mg
- Where
- 569 sites in United States, Argentina and 40 more
- Volunteers
- 5,390 people
- Sponsor
- Boehringer Ingelheim
Chronic Ischemic Stroke
Study of Modified Stem Cells (SB623) in Patients With Chronic Motor Deficit From Ischemic Stroke
Controlled study of stereotactic, intracranial injection of SB623 cells in patients with fixed motor deficits from ischemic stroke
- Trial name
- ACTIsSIMA (NCT02448641)
- Testing
- SB623 Implant (2.5M), SB623 Implant (5.0M)
- Where
- 65 sites in United States
- Volunteers
- 163 people
- Sponsor
- SanBio, Inc.